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INTRODUCTION 
The balance between tumour cell proliferation and tumour cell
apoptosis is a critical determinant of malignant tumour outgrowth.
To prevent programmed cell death, tumour cells frequently evolve
to express secreted growth factors that induce survival signalling
pathways, thereby repressing apoptosis. Recent experiments with
tumour cell lines and with a transgenic mouse model of β -cell
carcinogenesis indicated that insulin-like growth factors (IGFs) act
as survival factors to suppress tumour cell apoptosis (Baserga
et al, 1997; Rubin and Baserga, 1995; Christofori et al, 1994;
Monno et al, 2000). 
IGFs are important growth factors in many tumour types.
Several lines of evidence indicate that IGF-1 function may be
important in the pathogenesis of malignant neoplasms (Sullivan
et al, 1995; Kiess et al, 1997; Cianfarani and Rossi, 1997;
Zumkeller et al, 1999; Liu et al, 1998). Inhibition of IGF-1 expres-
sion in neuroblastoma cells has been shown to induce the regres-
sion of established tumours in mice. In addition, overexpression of
IGF-1 in neuroblastoma cells appears to prevent apoptosis and
enhance neuroblastoma tumorigenesis. 
The binding of IGFs to IGF-IR activates the receptor’s tyrosine
kinase activity, which triggers a cascade of reactions among a
number of molecules involved in the signal transduction pathway.
One key molecule that is activated in this manner is phosphoinosi-
tide 3-kinase (PI3K) (Jones and Clemmons, 1995; LeRoith et al,
1995), a lipid kinase that generates phosphorylated phosphatidyl-
inositol (PI) intermediates (such as PI3, 4,5-triphosphate, PIP3) in
the cytosolic leaflet of cellular membranes (Shepherd et al, 1995).
These PIP3 intermediates recruit other downstream signalling
molecules, particularly serine/threonine protein kinases such 
as AKT and atypical protein kinase C (PKC) isoforms to
membranes. Membrane recruitment of these molecules facilitates
their interaction with upstream regulators, including the serine
kinase 3-phosphoinositide-dependent kinase 1 (PDK1), which
phosphorylate and activate them. 
Other signal transduction pathways that are initiated by IGF-1R
may also exist (Lopaczynski et al, 1999). Activation of IGF-1R by
ligand binding is required for IGF-1R to mediate the actions of
IGFs. In addition to mediating the mitogenic and anti-apoptotic
actions of IGFs, IGF-1 is involved in cell transformation. In vitro
experiments have shown that removal of IGF-1R from the cell
membrane by eliminating the IGF-1R gene, by suppressing its
expression or by inhibiting its function, can abolish cell trans-
formation (Baserga et al, 1995). 
Some tumour-suppressor gene products have a profound impact
on the IGF family. Wild-type p53 protein induces the expression of
IGF binding protein-3 (IGFBP-3), represses the transcription of
IGF-II and suppresses IGF-1 expression (Buckbinder et al, 1995;
Zhang et al, 1996, 1998; Werner et al, 1996; Webster et al, 1996;
Ohlsson et al, 1998). When IGF-1-induced DNA synthesis takes
place in breast cancer cells, p53 can lose its function by under-
going phosphorylation and relocation from the nucleus to the
cytoplasm (Takahashi et al, 1993). 
In the past decade, a family of low-molecular-weight com-
pounds, Tyrphostins, have been synthesized and identified as
potent inhibitors of protein tyrosine kinases (PTKs), and different
members of the Tyrphostin family recognize PTKs of different
growth factor receptors such as epidermal growth factor receptor
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2These authors contributed equally to the work. (EGFR), insulin-like growth factor receptor (IGF-1R) in a
selective manner (Gazit et al, 1989). 
Tyrphostin AG 1024, one tyrosine kinase inhibitor specifically
targeting IGF-1 receptor, is metabolized intracellularly, creating
substances with increased activity towards the receptor and down-
regulated activity of Akt kinase. The objective of this study was to
examine the potential therapeutic purpose of Tyrphostin AG 1024
in combination with irradiation to counteract tumour cell prolifer-
ation and to modulate cellular radiosensitivity and apoptosis in a
human breast cancer cell line, MCF-7. 
MATERIALS AND METHODS 
Materials 
All materials and chemicals were purchased from Sigma (St Louis,
MC, USA) unless noted otherwise. The inhibitor of IGF-1R,
Tyrphostin AG 1024 was purchased from Alexis Biochemicals.
Akt, phospho-Akt, and NIH-3T3 PDGF-treated protein were
purchased from New England Biolabs, Inc. Bax and bcl-2, and p21
antibodies were purchased from Santa Cruz Biotechnology, Inc. 
Horseradish peroxidase-linked anti-rabbit and anti-mouse
antibody were from Jackson ImmunoResearch Laboratory Inc.;
molecular markers and fetal bovine serum were from Biological
Industries and ECL was purchased from Amersham Biotech Com.
ApopTag™ Plus apoptosis Detection Kit-Fluorescence was
purchased from Oncor Inc. 
Cell line 
MCH-7 was maintained in RPMI 1640 medium supplemented
with 10% fetal bovine serum, 100 U/ml of penicillin and strepto-
mycin, 2 mM L-glutamine at 37˚C in a humidified atmosphere of
5% CO2. 
IGF1R inhibitor treatment 
The anti-proliferative effect of Tyrphostin AG 1024 in vitro was
examined following replicate plating of a known number of single
cells. After incubation of 24 h, 10 nM/ml Tyrphostin AG 1024
were added to the medium and cells were trypsinized, stained with
trypan blue and counted with a haemocytometer at indicated time
intervals. 
Clonogenic survival 
Survival following exposure to irradiation and inhibitor of IGF-1R
Tyrphostin AG 1024 was defined as the ability of the cells to main-
tain their clonogenic capacity and form colonies. Briefly, after
treating with Tyrphostin AG 1024 10 nM/ml for 48 h, cells were
trypsinized, counted, seeded, and irradiated for colony formation,
or irradiated first; cells were trypsinized, counted and seeded, and
then exposed to Tyrphostin AG 1024 for 48 h for colony forma-
tion. Following an incubation interval of 2 weeks, colonies were
stained with crystal violet and manually counted. Colonies
consisting of ≥ 50 cells were scored. Differences in the percentage
of cell survivals among treatment groups were assessed by two-
sided student test. 
Apoptosis analysis (TUNEL assay) 
Apoptosis was evaluated by dual staining of MCF-7 with fluores-
ceine anti-digoxigenin and propidium iodide, as previously
described (Schmitz, 1991). Briefly, fixed cells were washed with
PBS, suspended in TdT buffer with TdT enzyme and Dig-dUTP
for 60 min, and suspended in FITC blocking solution with anti-
Dig-Fluorescein for 30 min at room temperature and kept in a dark
place. Cells were then rinsed in buffer and resuspended in
propidium iodide/RNase A solution for 30 min then analyzed by
flow cytometry. 
Expression of phospho-Akt1, Bax, p53, bcl-2 and p21 
Western blot 
After treatment, cells were lysed with Tween-20 lysis buffer
(50 mM HEPES pH 7.4, 15 mM NaCl, 0.1% Tween-20, 10%
glycerol, 2.5 mM EGTA, 1 mM EDTA, 1 mM phenylmethy-
sulfonyl fluoride, and inhibitor for proteinases) and sonicated.
Equal amounts of proteins were analyzed by SDS-PAGE.
Thereafter, proteins were transferred to nitrocellulose membranes
and analyzed by specific antibodies against phospho-Akt1
(ser473), Bax and β -actin. Proteins were detected via incubation
with horseradish peroxidase-conjugated secondary antibodies and
the enhanced chemiluminescence detection system. β -actin was
used as a control for loading. 
RESULTS 
Proliferation inhibited by Tyrphostin AG 1024 
Proliferation curves were evaluated in MCF-7 following the addi-
tion of an inhibitor of IGF-lR Tyrphostin AG 1024 with a different
time interval and irradiation. The growth inhibition profiles over
the 5-day exposure period are shown in Figure 1. Exposure to
Tyrphostin AG 1024 and irradiation inhibited proliferation of
MCF-7 in a time-dependent manner. This effect was more
pronounced when Tyrphostin AG 1024 was combined with irradi-
ation. In both the pre-irradiation and post-irradiation exposure
settings, treatment with Tyrphostin AG 1024 induced a marked
decrease of proliferation. 
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Figure 1 Tyrphostin AG 1024 inhibited proliferation of MCF-7, especially
when combined with irradiation. Known numbers of single cells from MCF-7
were seeded into 35-mmΦ dishes. After 24 hours, incubation, cells were
treated with AG 1024 10 nM/ml, irradiated with 4 Gy, AG 1024 10 nM/ml
combined with irradiation or irradiation combined with AG 1024 with 6 hours’
interval. Cells were harvested at different intervals and counted with trypan
blue dye exclusionRadiosensitivity enhanced by Tyrphostin AG 1024 
Experiments were designed to determine the effects of Tyrphostin
AG 1024 response combined with irradiation on clonogenic survival
of MCF-7 cells. Figure 2 depicts radiation-related survival curves
for cells exposed to Tyrphostin AG 1024 before or after exposure to
irradiation. Exposure of MCF-7 to 10 nM/ml Tyrphostin AG 1024
alone induced a reduction in plating efficiency of about 20%.
Increased cell killing was obtained using Tyrphostin AG 1024
combined with pre- or post-irradiation. The efficacy on cell killing
was more pronounced when the inhibitor was followed by irradia-
tion as compared to irradiation followed by the inhibitor (P < 0.05). 
Apoptosis induced by Tyrphostin AG 1024 
To determine whether apoptotic response was influenced by
Tyrphostin AG 1024 and/or irradiation, MCF-7 cells were exposed
to Tyrphostin AG 1024 10 nM/ml, irradiation (10 Gy) or both. As
shown in Figure 3, the percentage of apoptotic cells was 20.1%,
11.8% when cells were exposed to Tyrphostin AG 1024 alone or
irradiation alone, respectively, and was markedly increased when
Tyrphostin AG 1024 was combined with irradiation, especially
when cells were exposed first to Tyrphostin AG 1024 and irradi-
ated thereafter. 
Expression of phospho-Akt1 (ser473) influenced by
Tyrphostin AG 1024 in a time-responsive manner 
To measure the amount of phospho-Akt1, MCF-7 cells were
exposed to Tyrphostin AG 1024, lysed and immunoblotted for
phosphotyrosine-containing protein of 60 kD. As shown in Figure
4A, phospho-Akt1 was downregulated by Tyrphostin AG 1024 in a
time-responsive manner but the amount of Akt remained the same
(data not shown). The expression of phospho-Akt1 was more down-
regulated when cells were treated with starvation 24 h before adding
the inhibitor (data not shown). The expression of phospho-Akt1 was
not influenced by irradiation alone (Figure 4A). Figure 4B shows
that Tyrphostin AG 1024 downregulated phospho-Akt1, and this
effect was more pronounced when combined with irradiation. 
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Figure 2 Tyrphostin AG 1024 enhanced radiosensitivity. The influence of
Tyrphostin AG 1024 on intrinsic radiosensitivity was examined by clonogenic
survival in the MCF-7 cell line. MCF-7 cells were exposed to Tyrphostin AG
1024 10 nM/ml for 2 d before or after irradiation. Control cells were exposed
to irradiation without Tyrphostin AG 1024
Contrrol AG alone
Percentage of apoptosis in MCF-7
AG + RT RT + AG RT alone
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
Figure 3 Apoptosis was induced by Tyrphostin AG 1024 10 nM/ml and/or
irradiation 10 Gy at 48 h
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Figure 4 Expression and modulation of phospho-Akt1. (A) MCF-7 cells were treated with Tyrphostin AG 1024 10 nM/ml or irradiated with 4 Gy at defined time
interval. (B) MCF-7 cells were treated with 10 nM/ml, 20 nM/ml of Tyrphostin AG 1024, and/or combined with irradiation with 10 Gy at a 24-hour intervalsIncreased expression of Bax, p53 and p21, and
decreased expression of bcl-2 after Tyrphostin AG 1024
exposure 
To further investigate the effect of Tyrphostin AG 1024 on MCF-7,
we performed Western blots to examine the expression of Bax,
bcl-2, p21 and p53, known as critical regulators of apoptosis and
the cell cycle. As shown in Figure 5, treatment of MCF-7 cells
with Tyrphostin AG 1024 increased Bax, p21 and p53 expression,
and decreased the expression of bcl-2, especially when combined
with irradiation. 
DISCUSSION 
The proliferation of tumour cells during irradiation has been iden-
tified as a factor that adversely impacts tumour response and local
control (Fowler and Lindstrom, 1992). The approaches to reduce
the impact of tumour cell repopulation during radiation therapy
involve the delivery of biological agents that could reduce or
inhibit tumour cell proliferation. Modalities of treatment based on
growth factor-receptor interactions or on interference with their
signal transduction pathways, could be promising therapeutic
possibilities (Huang et al, 1999). Here, we investigated the ability
of Tyrphostin AG 1024, one inhibitor of IGF-1R, to inhibit prolif-
eration and also examined the capacity of Tyrphostin AG 1024 to
modulate radiosensitivity in a breast carcinoma cell line, MCF-7. 
The results have shown that Tyrphostin AG 1024 markedly
inhibited growth of MCF-7 cells (Figure 1). This growth inhibition
was associated with the induction of apoptosis. We also observed
that exposure of MCF-7 cells to the inhibitor of IGF-1 induced a
decreased expression of phospho-Akt1. These results were in good
agreement with those of Dupont et al, showing that IGF-1 acted to
increase P13K activity and Akt phosphorylation (Dupont et al,
2000). Yuan had also showed that apoptosis was induced in cancer
cells by inhibiting the PI3-kinase Akt pathway (Yuan et al, 2000). 
Our results are in agreement with previous studies, suggesting
that inactivation of IGF-1 function by the inhibitor could be essen-
tial for induction of apoptosis. Firstly, overexpression of Akt
inhibits apoptosis induced by various stimuli (Yuan et al, 2000).
Secondly, treatment of tumour with antibody or anti-sense oligonu-
cleotides targeting IGF-1R could decrease Akt protein expression
and sensitize cells to drug- or irradiated-induced programmed cell
death (Trojan et al, 1994; Shevelev et al, 1997; and Scotlandi et al,
1998). Finally, our results from kinetics experiments showed that
the levels and tyrosine activity of Akt1 were decreased before
MCF-7 apoptotic cell death induced the by IGF-1 inhibitor. 
Many components of the biological response to ionizing radia-
tion in mammalian cells are mediated through signal transduction,
cell cycle regulation, and DNA repair pathways (Coleman et al,
1996). Growth factors may play an important role in modulating
these cellular responses to irradiation. Indeed some reports have
shown a marked effect of epidermal growth factor (EGF) on the
radiosensitivity of cancer cells. For example, Wollman reported
that pre-irradiation exposure to EGF enhanced radioresistance in
MCF-7 cells, whereas Huang et al (1999) showed that exposure to
C225, an anti-EGF receptor monoclonal antibody, either before or
following irradiation, enhanced the radiosensitivity in a human
squamous cell carcinoma. 
So far, there was no report evaluating the effect of IGF-1R
inhibitor on the radiosensitivity of cancer cells. Here, we report for
the first time that exposure to inhibitor IGF-1R, Tyrphostin AG
1024, could enhance radiosensitivity in MCF-7 cells. It was
possible that the enhancement of radiosensitivity by Tyrphostin
AG 1024 could be mediated by mechanisms involving inhibition
of Akt phosphorylation and induction of apoptosis by increasing
expression of Bax and p53, and decreasing expression of bcl-2
(Figures 4 and 5). Indeed our results are in agreement with those of
previous studies showing that IGF-1 could inhibit apoptosis, stim-
ulate the expression of bcl-2 protein and in parallel suppress Bax
expression, which resulted in an increase in the relative amount of
the bcl/Bax heterodimer, thereby blocking initiation of the
apoptotic pathway (Minshall et al, 1997; Parrizas et al, 1997;
Wang et al, 1998). 
Here, for the first time we showed that Tyrphostin AG 1024 can
increase p21 expression, which can lead to a negative regulation
of cell proliferation (Figure 5). Indeed in a number of studies that
had used various cell lines, p21 has been described as a negative
regulator of cell cycle and proliferation. However these results
showing an increase of p21 after IGF-1R inhibitor exposure are
not in agreement with the data reported by Dupont et al (2000)
since they showed that IGF-1 was able to increase moderately
the level of p21 by interfering directly with the p21 promoter.
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Figure 5 Effect of Tyrphostin AG 1024 alone or with irradiation on the expression of Bax, p53, bcl-2 and p21. (A) MCF-7 cells were treated with 10 nM/ml
Tyrphostin AG 1024 at defined time interval. (B) MCF-7 cells were treated with 10 nM/ml of Tyrphostin AG 1024, combined with irradiation 10 Gy at a 24-hour
intervals, and then harvested and lysed at 48 hA possible explanation for this discrepancy might be that p53
expression was induced by AG 1024, which consequently would
increase the level of p21 (El-Deiry et al, 1993; Kim, 1997; Maestro
et al, 1997). 
In conclusion, our findings indicated that Tyrphostin AG 1024,
IGF-IR inhibitor, was an effective anti-proliferative agent for
breast carcinoma cells MCF-7. Growth inhibition was associated
with induction of apoptosis and an inhibition AKT/PI3 activity,
increased expression of Bax, p53 and p21 and decreased expres-
sion of bcl-2. In addition, this is the first report to show that an
IGF-1 inhibitor was able to markedly increase the response of
tumour cells to ionizing radiation. 
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